TLE3 as a candidate biomarker of response to taxane therapy

Breast Cancer Research

Volumn 11, Issue 2, 2009, Pages

  Kulkarni, Swati A ^a   Hicks, David G ^b   Watroba, Nancy L ^a   Murekeyisoni, Christine ^a   Hwang, Helena ^a   Khoury, Thaer ^a   Beck, Rodney A ^c   Ring, Brian Z ^d   Estopinal, Noel C ^e   Schreeder, Marshall T ^f   Seitz, Robert S ^c   Ross, Douglas T ^d  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^c Applied Genomics Inc   (United States)

^d Applied Genomics Inc   (United States)

^e Center for Cancer Care   (United States)

^f Clearview Cancer Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; METHOTREXATE; TRANSDUCIN LIKE ENHANCER 3; TUMOR MARKER; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; NUCLEAR PROTEIN; PROGESTERONE RECEPTOR; REPRESSOR PROTEIN; TLE2 PROTEIN, HUMAN;

ADULT; ARTICLE; BIVARIATE ANALYSIS; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; COHORT ANALYSIS; DISEASE FREE INTERVAL; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; VALIDATION STUDY; BREAST TUMOR; ENZYME IMMUNOASSAY; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS; TISSUE MICROARRAY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; COHORT STUDIES; CYCLOPHOSPHAMIDE; FEMALE; FLUOROURACIL; HUMANS; IMMUNOENZYME TECHNIQUES; METHOTREXATE; MIDDLE AGED; NUCLEAR PROTEINS; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; REPRESSOR PROTEINS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 68349103360     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr2241     Document Type: Article

References (26)

1. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, Demeter J, Perou CM, Lønning PE, Brown PO, Børresen-Dale AL, Botstein D. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003, 100:8418-8423. 166244, 12829800, 10.1073/pnas.0932692100.
2. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005, 365:1687-1717. 10.1016/S0140-6736(05)66544-0, 15894097, Early Breast Cancer Trialists' Collaborative Group (EBCTCG).
3. Martin M, Pienkowski T, Mackey J, Pawlicki M, Guastalla JP, Weaver C, Tomiak E, Al-Tweigeri T, Chap L, Juhos E, Guevin R, Howell A, Fornander T, Hainsworth J, Coleman R, Vinholes J, Modiano M, Pinter T, Tang SC, Colwell B, Prady C, Provencher L, Walde D, Rodriguez-Lescure A, Hugh J, Loret C, Rupin M, Blitz S, Jacobs P, Murawsky M, et al. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 2005, 352:2302-2313. 10.1056/NEJMoa043681, 15930421.
4. Rowinsky EK, Donehower RC. Paclitaxel (taxol). N Engl J Med 1995, 332:1004-1014. 10.1056/NEJM199504133321507, 7885406.
5. Crown J, O'Leary M, Ooi WS. Docetaxel and paclitaxel in the treatment of breast cancer: a review of clinical experience. Oncologist 2004, 9(Suppl 2):24-32. 10.1634/theoncologist.9-suppl_2-24, 15161988.
6. Nowak AK, Wilcken NR, Stockler MR, Hamilton A, Ghersi D. Systematic review of taxane-containing versus non-taxane-containing regimens for adjuvant and neoadjuvant treatment of early breast cancer. Lancet Oncol 2004, 5:372-380. 10.1016/S1470-2045(04)01494-9, 15172358.
7. Ward S, Simpson E, Davis S, Hind D, Rees A, Wilkinson A. Taxanes for the adjuvant treatment of early breast cancer: systematic review and economic evaluation. Health Technol Assess. 2007, 11:1-144. 17903394.
8. Ring BZ, Seitz RS, Beck R, Shasteen WJ, Tarr SM, Cheang MC, Yoder BJ, Budd GT, Nielsen TO, Hicks DG, Estopinal NC, Ross DT. Novel prognostic immunohistochemical biomarker panel for estrogen receptor-positive breast cancer. J Clin Oncol 2006, 24:3039-3047. 10.1200/JCO.2006.05.6564, 16809728.
9. Jennings BH, Ish-Horowicz D. The Groucho/TLE/Grg family of transcriptional co-repressors. Genome Biol 2008, 9:205. 2395242, 18254933, 10.1186/gb-2008-9-1-205.
10. Terry J, Saito T, Subramanian S, Ruttan C, Antonescu CR, Goldblum JR, Downs-Kelly E, Corless CL, Rubin BP, Rijn M, Ladanyi M, Nielsen TO. TLE1 as a diagnostic immunohistochemical marker for synovial sarcoma emerging from gene expression profiling studies. Am J Surg Pathol 2007, 31:240-246. 10.1097/01.pas.0000213330.71745.39, 17255769.
11. Chen G, Courey AJ. Groucho/TLE family proteins and transcriptional repression. Gene 2000, 249:1-16. 10.1016/S0378-1119(00)00161-X, 10831834.
12. Liu Y, Dehni G, Purcell KJ, Sokolow J, Carcangiu ML, Artavanis-Tsakonas S, Stifani S. Epithelial expression and chromosomal location of human TLE genes: implications for notch signaling and neoplasia. Genomics 1996, 31:58-64. 10.1006/geno.1996.0009, 8808280.
13. Leon C, Lobe CG. Grg3, a murine Groucho-related gene, is expressed in the developing nervous system and in mesenchyme-induced epithelial structures. Dev Dyn 1997, 208:11-24. 10.1002/(SICI)1097-0177(199701)208:1<11::AID-AJA2>3.0.CO;2-4, 8989517.
14. Whitfield ML, Sherlock G, Saldanha AJ, Murray JI, Ball CA, Alexander KE, Matese JC, Perou CM, Hurt MM, Brown PO, Botstein D. Identification of genes periodically expressed in the human cell cycle and their expression in tumors. Mol Biol Cell 2002, 13:1977-2000. 117619, 12058064, 10.1091/mbc.02-02-0030..
15. Symmans WF, Peintinger F, Hatzis C, Rajan R, Kuerer H, Valero V, Assad L, Poniecka A, Hennessy B, Green M, Buzdar AU, Singletary SE, Hortobagyi GN, Pusztai L. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol 2007, 25:4414-4422. 10.1200/JCO.2007.10.6823, 17785706.
16. Allen T, van Tuyl M, Iyengar P, Jothy S, Post M, Tsao MS, Lobe CG. Grg1 acts as a lung-specific oncogene in a transgenic mouse model. Cancer Res 2006, 66:1294-1301. 10.1158/0008-5472.CAN-05-1634, 16452182.
17. Nakaya HI, Beckedorff FC, Baldini ML, Fachel AA, Reis EM, Verjovski-Almeida S. Splice variants of TLE family genes and up-regulation of a TLE3 isoform in prostate tumors. Biochem Biophys Res Commun 2007, 364:918-923. 10.1016/j.bbrc.2007.10.097, 18273443.
18. Hasson P, Egoz N, Winkler C, Volohonsky G, Jia S, Dinur T, Volk T, Courey AJ, Paroush Z. EGFR signaling attenuates Groucho-dependent repression to antagonize Notch transcriptional output. Nat Genet 2005, 37:101-105.
19. Hasson P, Paroush Z. Crosstalk between the EGFR and other signalling pathways at the level of the global transcriptional corepressor Groucho/TLE. Br J Cancer 2007, 96(Suppl):R21-25.
20. van Agthoven T, Sieuwerts AM, Meijer-van Gelder ME, Look MP, Smid M, Veldscholte J, Sleijfer S, Foekens JA, Dorssers LC. Relevance of breast cancer antiestrogen resistance genes in human breast cancer progression and tamoxifen resistance. J Clin Oncol 2009, 27:542-549. 10.1200/JCO.2008.17.1462, 19075277.
21. van Agthoven T, Veldscholte J, Smid M, van Agthoven TL, Vreede L, Broertjes M, de Vries I, de Jong D, Sarwari R, Dorssers LC. Functional identification of genes causing estrogen independence of human breast cancer cells. Breast Cancer Res Treat 2009, 114:23-30. 10.1007/s10549-008-9969-5, 18351453.
22. Sekiya T, Zaret KS. Repression by Groucho/TLE/Grg proteins: genomic site recruitment generates compacted chromatin in vitro and impairs activator binding in vivo. Mol Cell 2007, 28:291-303. 2083644, 17964267, 10.1016/j.molcel.2007.10.002.
23. Andre F, Hatzis C, Anderson K, Sotiriou C, Mazouni C, Mejia J, Wang B, Hortobagyi GN, Symmans WF, Pusztai L. Microtubule-associated protein-tau is a bifunctional predictor of endocrine sensitivity and chemotherapy resistance in estrogen receptor-positive breast cancer. Clin Cancer Res 2007, 13:2061-2067. 10.1158/1078-0432.CCR-06-2078, 17404087.
24. Pusztai L. Markers predicting clinical benefit in breast cancer from microtubule-targeting agents. Ann Oncol 2007, 18(Suppl 12):xii15-20. 10.1093/annonc/mdm534, 18083698.
25. Hayes DF, Thor AD, Dressler LG, Weaver D, Edgerton S, Cowan D, Broadwater G, Goldstein LJ, Martino S, Ingle JN, Henderson IC, Norton L, Winer EP, Hudis CA, Ellis MJ, Berry DA, . Cancer and Leukemia Group B (CALGB) Investigators HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med 2007, 357:1496-1506. 10.1056/NEJMoa071167, 17928597, Cancer and Leukemia Group B (CALGB) Investigators.
26. Sparano JA, Wang M, Martino S, Jones V, Perez EA, Saphner T, Wolff AC, Sledge GW, Wood WC, Davidson NE. Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med 2008, 358:1663-1671. 10.1056/NEJMoa0707056, 18420499.